Skip to main content
Premium Trial:

Request an Annual Quote

Affymetrix to Appear on S&P Midcap 400 Index Beginning Dec. 30

NEW YORK, Dec. 28 (GenomeWeb News) - Standard & Poor's will add Affymetrix to its S&P MidCap 400 Index Dec. 30, the Index said yesterday.

 

Affy will join Beckman Coulter and Invitrogen, the only other genomic tool vendors tracked by the Index.

 

The Index, launched in 1991, tracks a diverse group of medium-sized UScompanies, according to Streetauthority.com. These companies have a market capitalization of between $2 billion and $10 billion, according to the service.

 

Streetauthority.com said the MidCap 400 "is an important benchmark for many fund managers who invest in this segment" and it "contains solid firms with good track records that are simply not large enough to be included in the much larger S&P 500 index."

 

The Index's current constituents can be seen here.

The Scan

Missed Early Cases

A retrospective analysis of blood samples suggests early SARS-CoV-2 infections may have been missed in the US, the New York Times reports.

Limited Journal Editor Diversity

A survey finds low diversity among scientific and medical journal editors, according to The Scientist.

How Much of a Threat?

Science writes that need for a provision aimed at shoring up genomic data security within a new US bill is being questioned.

PNAS Papers on Historic Helicobacter Spread, Brain Development, C. difficile RNAs

In PNAS this week: Helicobacter genetic diversity gives insight into human migrations, gene expression patterns of brain development, and more.